Abstract
The ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) has demonstrated clinical efficacy in newly diagnosed Acute Myeloid Leukemia (AML), particularly in overcoming resistance seen with the Azacitidine-Venetoclax (VA) combination and reducing the toxicity of traditional "3+7" chemotherapy. This study utilizes single-cell RNA sequencing (scRNA-seq) to characterize the bone marrow (BM) microenvironment in AML patients across various clinical states: diagnosis, remission, relapse, and refractory disease. Our analysis identifies distinct immune cell signatures—including exhausted TIGIT+ CD8+ T cells and specific monocyte clusters—that correlate with clinical outcomes. Furthermore, we observe significant downregulation of p53 signaling in refractory blasts and MHC Class II-related genes in relapse-associated T cells. These findings provide a high-resolution map of the AML microenvironment under ABC-14 therapy, offering insights for the development of targeted therapeutic strategies.
Introduction
Acute Myeloid Leukemia (AML) treatment has traditionally relied on intensive "3+7" induction chemotherapy. While effective, its high toxicity and the emergence of drug resistance necessitate more refined therapeutic approaches. The combination of Azacitidine and Venetoclax (VA) represented a significant advancement, yet resistance remains a challenge.
The "ABC-14" regimen incorporates Chidamide, a histone deacetylase inhibitor, to enhance the efficacy of the VA backbone. Preliminary data (2023 ASH Poster #1522) suggests ABC-14 is comparable to "3+7" in efficacy while offering a superior safety profile and better outcomes for specific subtypes like M4/M5. To optimize this regimen, it is critical to move beyond the malignant "seeds" (blasts) and understand the cellular and molecular dynamics of the bone marrow "soil" (microenvironment) that drive either continuous complete remission (CCR) or treatment failure.
Methodology
We performed scRNA-seq on bone marrow aspirates from 15 AML patients (6 at diagnosis, 3 in CCR, 2 at short-term relapse, and 4 refractory cases) and healthy individuals. Samples were obtained from the Guangdong Provincial People's Hospital under ethical guidelines with informed consent. The bioinformatics workflow included:
- Cell Clustering and Annotation: Identification of blasts, monocytes, T cells, and macrophages.
- CNV Estimation: Distinguishing malignant blasts from healthy hematopoietic cells via Copy Number Variation analysis.
- Differential Expression Analysis (DEGs): Identifying genes uniquely expressed in CCR versus relapse/refractory groups.
- Pathway Enrichment: Utilizing GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) databases to map altered biological processes.
Results
Immune Signatures of Remission and Relapse
Our analysis revealed that the cellular composition of the bone marrow microenvironment differs significantly based on patient response:
- Remission (CCR) Group: Characterized by an enrichment of specific CD14+ monocyte clusters expressing IFIT1, S100A12, HLA-DPB1, and AQP9. These markers suggest a more robust and functional innate immune presence associated with successful treatment.
- Relapse Group: Associated with an increase in CD16+ monocytes, C1QB+ macrophages, and exhausted TIGIT+ CD8+ T cells. The presence of TIGIT, a known immune checkpoint, indicates a state of T-cell exhaustion that may facilitate leukemic escape and disease recurrence.
Molecular Drivers of Resistance
We identified key molecular pathways that are downregulated in patients who fail to respond to ABC-14:
- p53 Signaling: Primary refractory patients and those with post-therapy residual blasts showed a significant downregulation of genes involved in p53-mediated signal transduction. As p53 is essential for inducing apoptosis in response to DNA damage, its suppression likely contributes to primary drug resistance.
- Antigen Presentation: In the relapse group, a specific T-cell cluster exhibited downregulation of MHC Class II genes and T-cell activation pathways. This suggests a mechanism of immune evasion where the leukemia cells effectively hide from the adaptive immune system by preventing the presentation of peptide antigens.
Discussion
This study provides a comprehensive single-cell landscape of AML under the ABC-14 regimen. The identification of exhausted T cells and immunosuppressive monocyte/macrophage populations in relapsed patients suggests that combining ABC-14 with immune checkpoint inhibitors (e.g., anti-TIGIT) could potentially improve clinical outcomes. Additionally, the downregulation of p53 and MHC II pathways highlights specific molecular vulnerabilities that could be targeted to overcome primary resistance and prevent relapse.
While limited by a small cohort of 15 cases, these results lay the groundwork for larger validation studies. Future work will focus on determining whether these cellular signatures are causative of relapse or secondary to it, ultimately facilitating the development of personalized therapeutic strategies for relapsed/refractory AML patients.
Summary updated